Drug Profile

IG 002 - Intergalactic Therapeutics

Alternative Names: IG-002 - Intergalactic Therapeutics; IG002

Latest Information Update: 30 Jun 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Intergalactic Therapeutics
Class Eye disorder therapies; Gene therapies
Mechanism of Action ATP binding cassette transporter subfamily A member 4 replacements; Gene transference

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Preclinical Retinal disorders

Most Recent Events

27 Jun 2023 Pharmacodynamics data from a preclinical study in Retinal disorders released by Intergalactic therapeutics
11 May 2023 Intergalactic Therapeutics files an IND application for Retinal disorder (Intraocular) in first half of 2024
11 May 2023 Intergalactic Therapeutics plans a phase I clinical trial in 2024

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com